5月28日，科伦博泰生物盘中下跌3.21%，报458.8港元，成交额1.15亿港元。消息面上，此前科伦博泰连续多日因ASCO年会临床数据利好及野村上调目标价等催化大幅上涨，但近日有关科伦系"三驾马车"全面失速的报道引发市场对基本面的重新审视。
据披露，科伦博泰2025年营收20.58亿元，同比增长6.5%，但净亏损扩大至3.82亿元，较上年同期亏损2.67亿元进一步恶化，主要原因为授权及里程碑收入同比大幅减少、研发费用与商业化投入高企。母公司科伦药业及川宁生物核心盈利指标亦全线大幅下滑，"增收不增利"的财务现实与管线利好之间的落差令部分资金选择获利了结。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.